Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pyrimethamine Clear all
Completed Phase 1 Interventional

A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS

NCT00000966
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Azithromycin, Pyrimethamine, Leucovorin calcium
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Worcester, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2008 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B...

NCT02511054
View directory record Official record
Conditions
Malaria
Interventions
Chloroquine (CQ), Pyrimethamine (PYR), Sanaria PfSPZ Challenge (NF54)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)

NCT01083667
View directory record Official record
Conditions
Familial Amyotrophic Lateral Sclerosis
Interventions
Pyrimethamine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2017 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose Escalation PfSPZ-CVac

NCT03083847
View directory record Official record
Conditions
Malaria
Interventions
Chloroquine Phosphate, Pyrimethamine, Sanaria PfSPZ Challenge
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2021 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Not applicable Interventional

A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine

NCT00001994
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Atovaquone
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Los Angeles, California • Oakland, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 1 Interventional

Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome

NCT00013689
View directory record Official record
Conditions
Autoimmune Disease, Lymphoproliferative Disorder
Interventions
Fansidar (pyrimethamine and sulfadoxine)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 2 Interventional

Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis

NCT00000794
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Sulfadiazine, Clarithromycin, Atovaquone, Pyrimethamine, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
16
States / cities
Los Angeles, California • Miami, Florida • Honolulu, Hawaii + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 3 Interventional

A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)

NCT00000727
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate, Pyrimethamine, Sulfamethoxazole/Trimethoprim, Sulfadoxine/Pyrimethamine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Not applicable Interventional

A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS

NCT00000674
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Pyrimethamine, Leucovorin calcium, Clindamycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Sep 3, 2026, 7:05 PM EDT
Recruiting Phase 4 Interventional

Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

NCT00004317
View directory record Official record
Conditions
Toxoplasmosis
Interventions
Leucovorin calcium, Pyrimethamine, Spiramycin, Sulfadiazine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 13, 2009 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Early Phase 1 Interventional

Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT05678348
View directory record Official record
Conditions
Head and Neck Cancer, Cancer of the Head and Neck
Interventions
Pyrimethamine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Not applicable Interventional

Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

NCT00002064
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Pyrimethamine, Clindamycin
Drug
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.

NCT04086719
View directory record Official record
Conditions
Healthy Male Volunteers
Interventions
BMS-986165, Pyrimethamine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 3, 2026, 7:05 PM EDT
Withdrawn Phase 1 Interventional

Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS)

NCT03057990
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Pyrimethamine
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 1 Interventional

Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome

NCT00065390
View directory record Official record
Conditions
Autoimmune Disease, Lymphatic Disease, Lymphoproliferative Disorder
Interventions
Pyrimethamine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT01066663
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions
pyrimethamine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 2 Interventional

Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients

NCT00000643
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Pyrimethamine, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
24
States / cities
Palo Alto, California • Torrance, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 3, 2026, 7:05 PM EDT
Withdrawn Phase 1 Interventional

A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis

NCT00679744
View directory record Official record
Conditions
G(M2) Ganglioside, Tay-Sachs Disease Ganglioside, Sandhoff Disease Ganglioside
Interventions
Pyrimethamine
Drug
Lead sponsor
Exsar Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2013 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 1 Interventional

A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients

NCT00000973
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Pyrimethamine, Leucovorin calcium, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Not applicable Interventional

A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection

NCT00000666
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Pyrimethamine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
16
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2012 · Synced Sep 3, 2026, 7:05 PM EDT